Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Artery Restenosis Clear all
Completed Phase 2 Interventional

Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries

NCT00140101
View directory record Official record
Conditions
Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
74
States / cities
Huntsville, Alabama • Gilbert, Arizona • La Jolla, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon

NCT04985773
View directory record Official record
Conditions
Coronary Stenosis, Coronary Artery Stenosis, In-stent Restenosis
Interventions
Lacrosse NSE ALPHA coronary dilatation catheter
Device
Lead sponsor
Infraredx
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Palo Alto, California • Lexington, Kentucky • Maplewood, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting No phase listed Observational

Abbott Vascular Medical Device Registry

NCT04573660
View directory record Official record
Conditions
Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism, Arterial Embolism
Interventions
Coronary and peripheral stents, Pacing catheters, Vascular plugs, Measurement and imaging (FFR and OCT), Peripheral dilatation catheters, Coronary dilatation catheters, Coronary and peripheral guidewires, Vessel closure/compression devices, Vascular access introducers
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2Phase 3 Interventional

Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis

NCT00287573
View directory record Official record
Conditions
Coronary Restenosis
Interventions
TAXUS Express2, Brachytherapy (beta source)
Device · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional

SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents

NCT00714545
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis
Interventions
Intracoronary brachytherapy
Radiation
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional

In Stent ELUTES Study

NCT00225680
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
drug eluting coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional

The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions

NCT00217269
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT PRIME Clinical Trial

NCT00916370
View directory record Official record
Conditions
Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Core size Xience Prime, Xience Prime Long Lesion (LL)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
56
States / cities
Fairhope, Alabama • Scottsdale, Arizona • Sacramento, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational

EXCEL Clinical Trial (Universal Registry)

NCT01205789
View directory record Official record
Conditions
Chronic Coronary Occlusion, Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed No phase listed Observational

Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System

NCT00852176
View directory record Official record
Conditions
Coronary In-stent Restenosis
Interventions
Not listed
Lead sponsor
Best Vascular, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 24, 2026, 1:07 AM EDT
Active, not recruiting Not applicable Interventional

SELUTION SLR™ 014 In-stent Restenosis

NCT04280029
View directory record Official record
Conditions
Coronary Restenosis
Interventions
SELUTION SLR 014 DEB, Standard of Care
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
34
States / cities
Loma Linda, California • Los Angeles, California • Torrance, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational

PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions

NCT00180466
View directory record Official record
Conditions
Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
22
States / cities
Phoenix, Arizona • San Jose, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 24, 2010 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational Results available

XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study

NCT01894152
View directory record Official record
Conditions
Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease, Coronary Restenosis, Myocardial Infarction, Stent Thrombosis, Vascular Disease
Interventions
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional

Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)

NCT00963781
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Thrombosis
Interventions
Medtronic Endeavor Stent, Reduced duration (6 months) DAPT
Device · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional

V-Flex Plus PTX Drug Eluting Coronary Stent

NCT00225693
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
drug eluting coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Jul 24, 2026, 1:07 AM EDT
Recruiting Not applicable Interventional

Virtue® SAB in the Treatment of Coronary ISR Trial

NCT07045194
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Virtue Sirolimus AngioInfusion Balloon, AGENT™ Paclitaxel Drug-Coated Balloon
Device
Lead sponsor
Orchestra BioMed, Inc
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
15
States / cities
Gainesville, Florida • Pensacola, Florida • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 3 Interventional

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

NCT00165035
View directory record Official record
Conditions
Coronary Disease
Interventions
CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Durham, North Carolina • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

NCT02229864
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Coronary artery stenting: Absorb BVS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Jul 24, 2026, 1:07 AM EDT
Withdrawn No phase listed Observational

REWARDS- In-stent Restenosis

NCT03008772
View directory record Official record
Conditions
In-Stent Coronary Artery Restenosis
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 4 Interventional Results available

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort

NCT01106534
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
Drug · Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
144
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Phase 2 Interventional

A Safety Study of ABI-007 for In-Stent Restenosis

NCT00093223
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease
Interventions
Paclitaxel Nanoparticle Albumin Bound
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 24, 2026, 1:07 AM EDT
Completed Not applicable Interventional Results available

EXCEL Clinical Trial

NCT01205776
View directory record Official record
Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Percutaneous Coronary Intervention, CABG
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Jul 24, 2026, 1:07 AM EDT
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Jul 24, 2026, 1:07 AM EDT